Clinical Trials - February 12, 2014
Phledpharma announce results from Pliant study
The results from the first part of the PLIANT study show that PledOx was well tolerated by patients treated with FOLFOX chemotherapy. Treatment with FOLFOX often causes severe painful sensory disorders known as neuropathies. These severe side-effects did not occur in patients who were pre-treated with PledOx, a compound that among other properties prevents severe […]
Collaboration - February 12, 2014
New European program targets novel antibiotics
More than 30 European universities and companies are joining forces in a 6 year programme funded by the Innovative Medicines Initiative (IMI) to develop novel antibiotics. The initiative is led by GlaxoSmithKline and Uppsala University. The novel antibiotics are being developed against Gram-negative pathogens in a project called ENABLE (European Gram Negative Antibacterial Engine). The ENABLE […]
Drug Development Pharma - February 12, 2014
AstraZeneca’s Onglyza on review
The diabetes drug Onglyza is under the FDA’s microscope as the agency said it would review possible heart risks associated with the medication. The decision comes after a study published in the New England Journal of Medicine. The study flagged an increase in heart failure hospitalizations among patients who used Onglyza (saxagliptin). The active ingredient is […]
Uncategorized - February 10, 2014
Drug-resistant tuberculosis on the rise
An extensive sample of patients revealed new drug-resistant strains of tuberculosis particularly in Eastern Europe. The evolution and contagion methods of the Mycobacterium tuberculosis bacterium which causes tuberculosis were under scrutiny in a major international study with particular focus on Russian tuberculosis patients. The study sequenced the genome of the tuberculosis bacterium based on 1,000 patient […]
Biotech Business - February 10, 2014
Topotarget gets green light from FDA
Topotarget A/S announces that the FDA has granted acceptance to file and priority review for the Beleodaqtm NDA for the treatment of relapsed or refractory PTCL. In December 2013, Topotarget’s US partner, Spectrum Pharmaceuticals, submitted a New Drug Application (NDA) for BeleodaqTM in relapsed or refractory (R/R) peripheral T-cell lymphoma (PTCL) to the US Food […]
Agreement - February 10, 2014
Sectra signs large healthcare agreement
The IT and medtech company has announced an order to the value of SEK 32 million for a four-year agreement. The agreement includes development, maintenance and support for a Scandinavian customer’s regional IT solution for managing medical images and patient information, the Sectra RIS and PACS. “We work purposefully to increase customer satisfaction by providing […]
